CTLA4 and neoplasm: That depletion of MDSCs can sensitize tumors to ICB and improved outcome was recently elegantly shown by depleting the gMDSCs using anti-Ly6G mAb combined with anti-CTLA4, which achieved tumor rejection in 100% of mice with murine oral cancer, whereas anti-CTLA4 alone only led to tumor rejection in 45% of cases [41].